Medicaid misclassification bill inspired by EpiPen passes Congress by Eric Sagonowsky Wednesday, April 3, 2019 After Mylan's high-profile EpiPen misclassification, lawmakers have passed a bill cracking down on Medicaid misrepresentations that cost taxpayers.
Big Pharma CEOs decide to show up at Senate pricing hearings by Eric Sagonowsky Wednesday, February 6, 2019 Sen. Charles Grassley, R-Iowa, vowed to haul pharma CEOs into Senate drug-pricing hearings. Now, several have heeded the call.
Senators look to end 'ripoff' of Medicaid misclassifications by Eric Sagonowsky Wednesday, December 5, 2018 Citing Mylan's EpiPen, two senators introduced a bill cracking down on drug misclassifications that cost Medicaid millions in underpaid rebates.
Sen. Wyden probes 'sweetheart' deal between Pfizer, Trump by Eric Sagonowsky Thursday, July 12, 2018 Sen. Ron Wyden wants to know more about why Pfizer CEO Ian Read agreed to defer the company's July price hikes.
AbbVie Humira patents in Bermuda enable big tax savings: Reuters by Eric Sagonowsky Wednesday, June 20, 2018 AbbVie has stored dozens of Humira patents in Bermuda, allowing it to lower its corporate tax rate, according to Reuters.
Novartis scandal ratchets up with Senate probe into Cohen deal by Tracy Staton Friday, May 11, 2018 If Novartis thought public statements this week would silence questions about its $1.2 million contract with Michael Cohen, it was wrong.
Ex-Lilly exec Azar wins Trump's nomination for top HHS post by Eric Sagonowsky Monday, November 13, 2017 President Donald Trump tweeted his nomination for ex-Eli Lilly executive Alex Azar as HHS secretary Monday morning.
White House at work on drug pricing EO: report by Eric Sagonowsky Wednesday, June 14, 2017 If President Donald Trump can’t count on Congress to pass pricing legislation, his administration may go it alone.
Senator targets PBM 'secrecy' in new legislation by Eric Sagonowsky Wednesday, March 15, 2017 Sen. Ron Wyden is diving into the contentious issue of pharmacy benefit manager rebates.
